Partial epigenetic reprogramming of adult tissue
Transiently expressing reprogramming factors (OCT4, SOX2, KLF4) in adult cells to reset age-associated gene expression without erasing cell identity.
State of the art
Life Biosciences ER-100 (AAV-delivered OSK switched on by oral doxycycline) dosed its first patient in June 2026 and reported interim tolerability in three glaucoma patients in October 2026, following nonhuman-primate NAION studies.
- Dose and duration window is narrow - too much OSK expression causes loss of cell identity and teratoma risk
- Doxycycline-gated expression gives coarse control over how far each cell is rewound
- No delivery route demonstrated for simultaneous reprogramming of many tissues in one body
Who’s working on it
- Life Biosciences ↗Startup
Received FDA clearance in January 2026 and dosed the first patient in its ER-100 OSK Phase 1 (NCT07290244); closed an 80 million dollar Series D in April 2026
- Altos LabsStartup
Launched in 2022 with 3 billion dollars to pursue reprogramming-based rejuvenation; its 2024 and 2025 papers extended lifespan in progeria mice and reversed mesenchymal drift
- Juan Carlos Izpisua BelmonteResearcherAltos Labs
Pioneered cyclic in vivo partial reprogramming and reported Cdkn2a-promoter-gated OSK extending mouse lifespan without increased tumour occurrence (2024)
- David SinclairResearcherHarvard Medical School
His OSK optic-nerve rejuvenation work is the basis of Life Biosciences ER-100, the first partial-reprogramming therapy dosed in humans
- Universidad Catolica San Antonio de MurciaAcademic lab
Co-funded and co-authored the Altos targeted partial reprogramming study published in Science Translational Medicine in 2024
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Dose-response and tumorigenicity studies of multi-tissue reprogramming in nonhuman primates, with cell-identity readouts | $$$ $100M – $1B |
| engineering | Tighter expression switches (small-molecule or circuit-gated) giving per-cell control of reprogramming depth | $$ $10M – $100M |
Depends on
Required by
No other capability builds on this directly.